search
Back to results

Different Volumes of Durolane in Knee OA

Primary Purpose

Knee Osteoarthritis

Status
Completed
Phase
Phase 2
Locations
Sweden
Study Type
Interventional
Intervention
Durolane 3 ml, Durolane 4,5 ml, Durolane 6 ml
Sponsored by
Galderma R&D
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Knee Osteoarthritis

Eligibility Criteria

40 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject (female or male)
  • 40-85 years of age
  • Unilateral knee pain fulfilling American College of Rheumatology (ACR) criteria for diagnosis of osteoarthritis(OA)
  • Radiographic evidence of OA in the study knee
  • WOMAC pain score of 7-17 in the study knee
  • WOMAC pain score of 2-3 in the study knee (WOMAC Likert 3.1 A1)
  • Subject normally active
  • Subject has attempted but not responded adequately to previous non-pharmacological therapy(ies)and to simple analgetics
  • Subject cooperative and able to communicate effectively with the investigators
  • Body mass index ≤ 35 kg/m2;
  • Signed informed consent obtained

Exclusion Criteria:

  • Knee effusion
  • Contralateral knee OA
  • Clinically significant joint pain from joints other than the knee
  • Previous intra-articular steroid injection into the study knee within the last 6 months
  • Previous intra-articular Hyaluronic Acid (HA) injection into the study knee within the last 9 months
  • Previous allergic type reaction to a HA product
  • Treatment with analgesics other than paracetamol (acetaminophen) (including topical agents for the knee) within 5 half lives of the drug prior to the baseline visit
  • Use of analgesics 48 hours preceding the baseline visit
  • Use of systemic glucocorticosteroids (excluding inhaled steroids) within the last 3 months
  • Treatment with glucosamine/chondroitin sulfate initiated within the past 3 months
  • Change in physical therapy for the knee within the last three months
  • Arthroscopy or other surgical procedure in the study knee within the past 12 months
  • Serious injuries to the study knee in the past
  • Any planned arthroscopy or other surgical procedure during the study period
  • Previous history or presence of active septic arthritis
  • Active skin disease or infection in the area of the injection site
  • Systemic active inflammatory condition or infection
  • Bleeding diathesis or use of anticoagulants
  • History of drug or alcohol abuse within 6 months
  • Any medical condition that in the opinion of the investigator makes the subject unsuitable for inclusion
  • Pregnant or breastfeeding woman or woman of childbearing potential not practicing adequate contraception
  • Involvement in other clinical trials

Sites / Locations

  • Torsten Adalberth
  • Christian Akermark
  • Johan Isacson

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Durolane 3ml

Durolane 4.5

Durolane 6 ml

Arm Description

Durolane 3 ml is an Intraarticular hyaluronic acid

Durolane 4.5 is an Intraarticular hyaluronic acid

Durolane 6 ml is an Intraarticular hyaluronic acid

Outcomes

Primary Outcome Measures

Change of Pain Over 26 Weeks (Change From Baseline)
The study aims to compare the change of pain for different volumes of study product over 26 weeks using WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain score that consists of 5 questions. It is a 5-graded Likert scale: None, Mild, Moderate, Severe or Extreme relating to how much pain the subject has experienced during the last 48 hours. The score of each dimension is calculated by simply adding the score (from 0 to 4) for each question.

Secondary Outcome Measures

Number of Participants With Adverse Events as a Measure of Safety and Tolerability From Baseline to 26 Weeks After Treatment.
Safety and tolerability will be assessed at each clinic visit (Baseline, 2, 6, 12, 18 and 26 weeks). Standard questions was used, "Since your last clinical visit have you had any health problems?".
WOMAC Stiffness Score (Change From Baseline)
The study aims to compare the change of stiffness for different volumes of study product over 26 weeks using WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) stiffness score that consists of 2 questions. It is a 5-graded Likert scale: None, Mild, Moderate, Severe or Extreme relating to how much stiffness the subject has experienced in the last 48 hours. The score of each dimension is calculated by simply adding the score (from 0 to 4) for each question.
WOMAC Physical Function Score (Change From Baseline)
The study aims to compare the physical function for different volumes of study product over 26 weeks using WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) physical function score that consists of 17 questions. It is a 5-graded Likert scale: None, Mild, Moderate, Severe or Extreme relating to performing daily physical activities the subject has experienced in the last 48 hours. The score of each dimension is calculated by simply adding the score (from 0 to 4) for each question.
Subject´s Global Assessment of the Status of the Study Knee (Change From Baseline)
The subject will assess his/her global status how the study knee affects them by using a 11-point numerical rating scale, Subject global assessment scale, from "very poor=0" to "excellent=10".

Full Information

First Posted
December 17, 2010
Last Updated
August 24, 2022
Sponsor
Galderma R&D
search

1. Study Identification

Unique Protocol Identification Number
NCT01265459
Brief Title
Different Volumes of Durolane in Knee OA
Official Title
Double-Blind, Randomized Study of Three Different Volumes of Durolane in Subjects With Osteoarthritis of the Knee
Study Type
Interventional

2. Study Status

Record Verification Date
March 2014
Overall Recruitment Status
Completed
Study Start Date
January 2011 (undefined)
Primary Completion Date
September 2011 (Actual)
Study Completion Date
November 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Galderma R&D

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to assess the safety and efficacy profiles of new single-injection volumes of Durolane in patients with knee OA.
Detailed Description
To assess the safety and efficacy profiles of different volumes of Durolane in patients with knee OA and compare with the current standard single-injection of the product. The study aims to investigate whether different volumes of Durolane compared to the standard injection volume will improve the benefit/risk profile.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Knee Osteoarthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
68 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Durolane 3ml
Arm Type
Experimental
Arm Description
Durolane 3 ml is an Intraarticular hyaluronic acid
Arm Title
Durolane 4.5
Arm Type
Experimental
Arm Description
Durolane 4.5 is an Intraarticular hyaluronic acid
Arm Title
Durolane 6 ml
Arm Type
Experimental
Arm Description
Durolane 6 ml is an Intraarticular hyaluronic acid
Intervention Type
Device
Intervention Name(s)
Durolane 3 ml, Durolane 4,5 ml, Durolane 6 ml
Intervention Description
Durolane is an intraarticular hyaluronic acid preparation
Primary Outcome Measure Information:
Title
Change of Pain Over 26 Weeks (Change From Baseline)
Description
The study aims to compare the change of pain for different volumes of study product over 26 weeks using WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain score that consists of 5 questions. It is a 5-graded Likert scale: None, Mild, Moderate, Severe or Extreme relating to how much pain the subject has experienced during the last 48 hours. The score of each dimension is calculated by simply adding the score (from 0 to 4) for each question.
Time Frame
26 weeks after treatment compared to baseline
Secondary Outcome Measure Information:
Title
Number of Participants With Adverse Events as a Measure of Safety and Tolerability From Baseline to 26 Weeks After Treatment.
Description
Safety and tolerability will be assessed at each clinic visit (Baseline, 2, 6, 12, 18 and 26 weeks). Standard questions was used, "Since your last clinical visit have you had any health problems?".
Time Frame
From baseline to 26 weeks after treatment
Title
WOMAC Stiffness Score (Change From Baseline)
Description
The study aims to compare the change of stiffness for different volumes of study product over 26 weeks using WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) stiffness score that consists of 2 questions. It is a 5-graded Likert scale: None, Mild, Moderate, Severe or Extreme relating to how much stiffness the subject has experienced in the last 48 hours. The score of each dimension is calculated by simply adding the score (from 0 to 4) for each question.
Time Frame
26 weeks after treatment compared to baseline
Title
WOMAC Physical Function Score (Change From Baseline)
Description
The study aims to compare the physical function for different volumes of study product over 26 weeks using WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) physical function score that consists of 17 questions. It is a 5-graded Likert scale: None, Mild, Moderate, Severe or Extreme relating to performing daily physical activities the subject has experienced in the last 48 hours. The score of each dimension is calculated by simply adding the score (from 0 to 4) for each question.
Time Frame
26 weeks after treatment compared to baseline
Title
Subject´s Global Assessment of the Status of the Study Knee (Change From Baseline)
Description
The subject will assess his/her global status how the study knee affects them by using a 11-point numerical rating scale, Subject global assessment scale, from "very poor=0" to "excellent=10".
Time Frame
26 weeks after treatment compared to baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject (female or male) 40-85 years of age Unilateral knee pain fulfilling American College of Rheumatology (ACR) criteria for diagnosis of osteoarthritis(OA) Radiographic evidence of OA in the study knee WOMAC pain score of 7-17 in the study knee WOMAC pain score of 2-3 in the study knee (WOMAC Likert 3.1 A1) Subject normally active Subject has attempted but not responded adequately to previous non-pharmacological therapy(ies)and to simple analgetics Subject cooperative and able to communicate effectively with the investigators Body mass index ≤ 35 kg/m2; Signed informed consent obtained Exclusion Criteria: Knee effusion Contralateral knee OA Clinically significant joint pain from joints other than the knee Previous intra-articular steroid injection into the study knee within the last 6 months Previous intra-articular Hyaluronic Acid (HA) injection into the study knee within the last 9 months Previous allergic type reaction to a HA product Treatment with analgesics other than paracetamol (acetaminophen) (including topical agents for the knee) within 5 half lives of the drug prior to the baseline visit Use of analgesics 48 hours preceding the baseline visit Use of systemic glucocorticosteroids (excluding inhaled steroids) within the last 3 months Treatment with glucosamine/chondroitin sulfate initiated within the past 3 months Change in physical therapy for the knee within the last three months Arthroscopy or other surgical procedure in the study knee within the past 12 months Serious injuries to the study knee in the past Any planned arthroscopy or other surgical procedure during the study period Previous history or presence of active septic arthritis Active skin disease or infection in the area of the injection site Systemic active inflammatory condition or infection Bleeding diathesis or use of anticoagulants History of drug or alcohol abuse within 6 months Any medical condition that in the opinion of the investigator makes the subject unsuitable for inclusion Pregnant or breastfeeding woman or woman of childbearing potential not practicing adequate contraception Involvement in other clinical trials
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Per-Erik Melberg, MD
Organizational Affiliation
Kristinelundskliniken, Kristinelundsgatan 13, 411 37 Göteborg
Official's Role
Principal Investigator
Facility Information:
Facility Name
Torsten Adalberth
City
Malmo
ZIP/Postal Code
211 36
Country
Sweden
Facility Name
Christian Akermark
City
Stockholm
ZIP/Postal Code
111 35
Country
Sweden
Facility Name
Johan Isacson
City
Upplands Vasby
ZIP/Postal Code
194 89
Country
Sweden

12. IPD Sharing Statement

Learn more about this trial

Different Volumes of Durolane in Knee OA

We'll reach out to this number within 24 hrs